Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CYTK Stock Forecast 2025-2026
$30.49
Current Price
$3.70B
Market Cap
Buy 18
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to CYTK Price Targets
+293.6%
To High Target of $120.00
+134.5%
To Median Target of $71.50
+34.5%
To Low Target of $41.00
CYTK Price Momentum
-1.6%
1 Week Change
-19.8%
1 Month Change
-37.8%
1 Year Change
-35.2%
Year-to-Date Change
-50.3%
From 52W High of $61.38
+4.0%
From 52W Low of $29.31
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Cytokinetics (CYTK) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CYTK and similar high-potential opportunities.
Latest CYTK Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, CYTK has a bullish consensus with a median price target of $71.50 (ranging from $41.00 to $120.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $30.49, the median forecast implies a 134.5% upside. This outlook is supported by 18 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 293.6% upside. Conversely, the most conservative target is provided by Ashwani Verma at UBS, suggesting a 34.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CYTK Analyst Ratings
18
Buy
3
Hold
0
Sell
CYTK Price Target Range
Low
$41.00
Average
$71.50
High
$120.00
Current: $30.49
Latest CYTK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CYTK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2025 | Needham | Serge Belanger | Buy | Reiterates | $72.00 |
| May 8, 2025 | Barclays | Gena Wang | Overweight | Maintains | $53.00 |
| May 7, 2025 | Citigroup | David Lebowitz | Buy | Maintains | $80.00 |
| May 7, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $80.00 |
| May 2, 2025 | Needham | Serge Belanger | Buy | Reiterates | $72.00 |
| May 2, 2025 | UBS | Ashwani Verma | Neutral | Maintains | $41.00 |
| Apr 24, 2025 | Barclays | Gena Wang | Overweight | Initiates | $55.00 |
| Apr 21, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Apr 15, 2025 | B of A Securities | Jason Zemansky | Neutral | Maintains | $54.00 |
| Apr 15, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Apr 10, 2025 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $78.00 |
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $72.00 |
| Apr 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Apr 3, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Reiterates | $78.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
| Feb 13, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Upgrade | $67.00 |
| Feb 7, 2025 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $78.00 |
| Feb 7, 2025 | Citigroup | David Lebowitz | Buy | Initiates | $86.00 |
| Feb 6, 2025 | Needham | Serge Belanger | Buy | Reiterates | $72.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $120.00 |
Cytokinetics, Inc. (CYTK) Competitors
The following stocks are similar to Cytokinetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cytokinetics, Inc. (CYTK) Financial Data
Cytokinetics, Inc. has a market capitalization of $3.70B with a P/E ratio of -5.8x. The company generates $19.22M in trailing twelve-month revenue with a -1,737.2% profit margin.
Revenue growth is +89.1% quarter-over-quarter, while maintaining an operating margin of -9,856.3% and return on equity of +435.5%.
Valuation Metrics
Market Cap
$3.70B
Enterprise Value
$3.71B
P/E Ratio
-5.8x
PEG Ratio
-5.7x
Price/Sales
192.4x
Growth & Margins
Revenue Growth (YoY)
+89.1%
Gross Margin
-6,223.1%
Operating Margin
-9,856.3%
Net Margin
-1,737.2%
EPS Growth
+89.1%
Financial Health
Cash/Price Ratio
+25.8%
Current Ratio
6.0x
Debt/Equity
-3.4x
ROE
+435.5%
ROA
-34.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cytokinetics, Inc. (CYTK) Business Model
About Cytokinetics, Inc.
What They Do
Develops muscle activators for medical treatments.
Business Model
Cytokinetics generates revenue through the discovery and commercialization of novel muscle activators aimed at treating diseases in neurology and cardiology. The company is engaged in clinical trials and partnerships to advance its small molecule drugs, which are designed to enhance muscle function in patients with conditions such as heart failure and ALS.
Additional Information
Headquartered in South San Francisco, Cytokinetics is positioned as a significant player in the biotechnology sector, focusing on innovative therapies that address unmet medical needs. The company's collaborative efforts and commitment to research highlight its potential for impactful contributions to patient care and the healthcare market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
498
CEO
Mr. Robert I. Blum
Country
United States
IPO Year
2004
Website
www.cytokinetics.comCytokinetics, Inc. (CYTK) Latest News & Analysis
Latest News
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Cytokinetics (NASDAQ:CYTK) investors. Interested parties can visit bgandg.com/CYTK for more information.
Why It Matters
Cytokinetics is under investigation, potentially signaling issues that could impact stock value, prompting investors to reassess their positions and risk exposure.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating Cytokinetics (NASDAQ:CYTK) for potential federal securities law violations after the FDA delayed the approval of its drug aficamten for hypertrophic obstructive cardiomyopathy.
Why It Matters
Cytokinetics faces potential legal issues and FDA delays, which could impact stock performance and investor confidence in its drug pipeline.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating Cytokinetics (NASDAQ:CYTK) for potential federal securities law violations. The FDA has delayed approval of its drug aficamten for further review.
Why It Matters
Cytokinetics faces potential legal issues and FDA delays, which could impact stock performance and investor sentiment regarding its drug pipeline and future profitability.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Cytokinetics (NASDAQ:CYTK) investors. Interested parties can find more information at bgandg.com/CYTK.
Why It Matters
The investigation into Cytokinetics may indicate potential legal issues or financial troubles, which could impact stock value and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
ATTENTION CYTK Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
4 days ago
Quick Summary
Levi & Korsinsky is investigating Cytokinetics (NASDAQ:CYTK) for potential federal securities law violations after the FDA delayed approval for its drug aficamten to review its risk management plan.
Why It Matters
Cytokinetics faces scrutiny over potential federal securities law violations and FDA delays on a key drug, which could impact stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Cytokinetics (NASDAQ: CYTK) investors. Interested parties can visit bgandg.com/CYTK for details.
Why It Matters
The investigation into Cytokinetics may indicate potential legal issues or financial irregularities, which could impact stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About CYTK Stock
What is Cytokinetics, Inc.'s (CYTK) stock forecast for 2025?
Based on our analysis of 27 Wall Street analysts, Cytokinetics, Inc. (CYTK) has a median price target of $71.50. The highest price target is $120.00 and the lowest is $41.00.
Is CYTK stock a good investment in 2025?
According to current analyst ratings, CYTK has 18 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $30.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CYTK stock?
Wall Street analysts predict CYTK stock could reach $71.50 in the next 12 months. This represents a 134.5% increase from the current price of $30.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cytokinetics, Inc.'s business model?
Cytokinetics generates revenue through the discovery and commercialization of novel muscle activators aimed at treating diseases in neurology and cardiology. The company is engaged in clinical trials and partnerships to advance its small molecule drugs, which are designed to enhance muscle function in patients with conditions such as heart failure and ALS.
What is the highest forecasted price for CYTK Cytokinetics, Inc.?
The highest price target for CYTK is $120.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 293.6% increase from the current price of $30.49.
What is the lowest forecasted price for CYTK Cytokinetics, Inc.?
The lowest price target for CYTK is $41.00 from Ashwani Verma at UBS, which represents a 34.5% increase from the current price of $30.49.
What is the overall CYTK consensus from analysts for Cytokinetics, Inc.?
The overall analyst consensus for CYTK is bullish. Out of 27 Wall Street analysts, 18 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $71.50.
How accurate are CYTK stock price projections?
Stock price projections, including those for Cytokinetics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 2:44 AM UTC